Collecting data on rare tumors in children and adolescents

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

The STEP registry aims to gather and analyze clinical data on rare tumors affecting children and adolescents to enhance diagnosis and treatment strategies. By conducting a continuous prospective collection of data, the study seeks to improve understanding of these rare conditions and their biological characteristics. Collaboration with international partners, particularly the European EXPeRT group, will facilitate the development of better treatment recommendations and establish a global network of specialists in rare tumors.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Diagnosis of a rare solid tumor
* Age at diagnosis: Neonatal period to 18 years (In the case of young adults, registration in the database and/or referral to advisory contact persons within the framework of the competence network can take place upon request and after declaration of consent.)
* Information, education, written consent of the patient or the guardian
* Not recorded in any of the existing clinical studies/ registers of the German Society for Pediatric Oncology and Hematology (GPOH)

Exclusion Criteria:

* Registration of the tumor diagnosis in a prospective therapy study/ another clinical registry of the GPOH
* Lack of information, explanation and/or written consent of the patient or the legal guardian.

Where it's running

• University Hospital Tübingen
  Tübingen, Germany Recruiting

Study contacts

• Study coordinator: Ines Brecht, PD Dr. med.
• Email: ines.brecht@med.uni-tuebingen.de
• Phone: +49 7071 29

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• AI-assisted Rare-Disease Diagnosis

  A multicenter randomized test to see if an AI diagnostic tool can help doctors make faster, more accurate rare-disease diagnoses for patients with unresolved symptoms.

  Recruiting at 3 sites Peking Union Medical College Hospital · Cangzhou and 11 other locations · NCT07650799

• Socio‑professional inclusion for young people (15–25) with childhood-onset rare genetic disabilities

  This project will try to see what makes it hard for 15–25‑year‑olds with childhood-onset rare genetic conditions to access higher education, internships, or work.

  Recruiting Imagine Institute · Paris, Île-de-France Region · NCT07527624

• Treatment approaches for AChR-antibody positive generalized myasthenia gravis in Russia.

  This project will look at which treatments adults in Russia with AChR-antibody positive generalized myasthenia gravis receive and how their symptoms and hospitalizations change over time.

  Recruiting at 7 sites AstraZeneca · Kazan' and 6 other locations · NCT07247279

• Long-term outcomes for people with immune TTP in the French national TMA cohort

  This project uses past medical records to see long-term health outcomes and complications in people in France who had immune thrombotic thrombocytopenic purpura (iTTP).

  Recruiting Assistance Publique - Hôpitaux de Paris · Paris · NCT07205861

• Rapid genetic testing and virtual genetic consults for newborns with unexplained birth defects in Texas

  This project will test rapid whole genome sequencing and virtual genetic consultations for seriously ill newborns in Texas to find genetic causes of birth defects.

  Recruiting Baylor College of Medicine · Houston, Texas · NCT07102966

• Identification of Cellular Biomarkers in Rare Eye Diseases

  This study tests whether specific gene and protein markers in cells and tears can distinguish adults with rare corneal diseases from others and relate to their eye symptoms.

  Recruiting Institut National de la Santé Et de la Recherche Médicale, France · Paris and 1 other locations · NCT07063719

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.